Which has better valuation and earnings, LIVN or ENOV?

LivaNova has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.26 -$242.47M $1.95 42.30 Enovis $2.25B 0.51 -$1.18B -$19.88 N/A

Is LIVN or ENOV more profitable?

LivaNova has a net margin of 7.48% compared to Enovis' net margin of -49.92%. LivaNova's return on equity of 16.48% beat Enovis' return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 7.48% 16.48% 7.59% Enovis -49.92% 10.32% 4.57%

Does the media prefer LIVN or ENOV?

In the previous week, Enovis had 2 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for Enovis and 3 mentions for LivaNova. LivaNova's average media sentiment score of 0.54 beat Enovis' score of 0.21 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enovis 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, NVST or ENOV?

Envista has higher revenue and earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Envista $2.72B 1.63 $47M $0.41 66.37 Enovis $2.25B 0.51 -$1.18B -$19.88 N/A

Is NVST or ENOV more profitable?

Envista has a net margin of 2.41% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Envista's return on equity. Company Net Margins Return on Equity Return on Assets Envista 2.41% 7.11% 3.91% Enovis -49.92% 10.32% 4.57%

Which has preferable valuation & earnings, MMED or ENOV?

MiniMed Group has higher revenue and earnings than Enovis. MiniMed Group is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiniMed Group $2.99B 1.43 -$190.96M -$0.68 N/A Enovis $2.25B 0.51 -$1.18B -$19.88 N/A

Is MMED or ENOV more profitable?

MiniMed Group has a net margin of 0.00% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat MiniMed Group's return on equity. Company Net Margins Return on Equity Return on Assets MiniMed Group N/A N/A N/A Enovis -49.92% 10.32% 4.57%

Does the media favor MMED or ENOV?

In the previous week, Enovis had 3 more articles in the media than MiniMed Group. MarketBeat recorded 5 mentions for Enovis and 2 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 0.96 beat Enovis' score of 0.21 indicating that MiniMed Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiniMed Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enovis 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ENOV or IRTC?

In the previous week, Enovis had 2 more articles in the media than iRhythm Technologies. MarketBeat recorded 5 mentions for Enovis and 3 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.23 beat Enovis' score of 0.21 indicating that iRhythm Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral iRhythm Technologies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, ENOV or WRBY?

Warby Parker has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enovis $2.25B 0.51 -$1.18B -$19.88 N/A Warby Parker $871.91M 3.62 $1.64M $0.02 1,473.90

Is ENOV or WRBY more profitable?

Warby Parker has a net margin of 0.15% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Warby Parker's return on equity. Company Net Margins Return on Equity Return on Assets Enovis -49.92% 10.32% 4.57% Warby Parker 0.15% 2.30% 1.18%

Does the media favor ENOV or WRBY?

In the previous week, Warby Parker had 3 more articles in the media than Enovis. MarketBeat recorded 8 mentions for Warby Parker and 5 mentions for Enovis. Warby Parker's average media sentiment score of 0.84 beat Enovis' score of 0.21 indicating that Warby Parker is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Warby Parker 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Enovis (ENOV) Competitors

$20.00 -0.71 (-3.41%)

Closing price 03:59 PM Eastern

Extended Trading

$20.64 +0.65 (+3.23%)

As of 04:18 PM Eastern

Compare

ENOV vs. LIVN, NVST, MMED, IRTC, and WRBY

Should you buy Enovis stock or one of its competitors? MarketBeat compares Enovis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enovis include LivaNova (LIVN), Envista (NVST), MiniMed Group (MMED), iRhythm Technologies (IRTC), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry.

How does Enovis compare to LivaNova?

LivaNova (NASDAQ:LIVN) and Enovis (NYSE:ENOV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

LivaNova presently has a consensus target price of $80.75, suggesting a potential downside of 2.10%. Enovis has a consensus target price of $44.50, suggesting a potential upside of 122.56%. Given Enovis' higher possible upside, analysts plainly believe Enovis is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Enovis	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

LivaNova has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Enovis has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

LivaNova has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.26	-$242.47M	$1.95	42.30
Enovis	$2.25B	0.51	-$1.18B	-$19.88	N/A

LivaNova has a net margin of 7.48% compared to Enovis' net margin of -49.92%. LivaNova's return on equity of 16.48% beat Enovis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Enovis	-49.92%	10.32%	4.57%

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 98.5% of Enovis shares are owned by institutional investors. 0.4% of LivaNova shares are owned by company insiders. Comparatively, 2.9% of Enovis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Enovis had 2 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for Enovis and 3 mentions for LivaNova. LivaNova's average media sentiment score of 0.54 beat Enovis' score of 0.21 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enovis	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

LivaNova beats Enovis on 8 of the 15 factors compared between the two stocks.

How does Enovis compare to Envista?

Envista (NYSE:NVST) and Enovis (NYSE:ENOV) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Envista has a net margin of 2.41% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	2.41%	7.11%	3.91%
Enovis	-49.92%	10.32%	4.57%

Envista has higher revenue and earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.72B	1.63	$47M	$0.41	66.37
Enovis	$2.25B	0.51	-$1.18B	-$19.88	N/A

98.5% of Enovis shares are owned by institutional investors. 1.0% of Envista shares are owned by company insiders. Comparatively, 2.9% of Enovis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Enovis had 5 more articles in the media than Envista. MarketBeat recorded 5 mentions for Enovis and 0 mentions for Envista. Enovis' average media sentiment score of 0.21 beat Envista's score of 0.00 indicating that Enovis is being referred to more favorably in the news media.

Company	Overall Sentiment
Envista	Neutral
Enovis	Neutral

Envista currently has a consensus price target of $28.67, suggesting a potential upside of 5.34%. Enovis has a consensus price target of $44.50, suggesting a potential upside of 122.56%. Given Enovis' stronger consensus rating and higher probable upside, analysts clearly believe Enovis is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Enovis	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Envista has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Enovis has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

Summary

Enovis beats Envista on 10 of the 16 factors compared between the two stocks.

How does Enovis compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and Enovis (NYSE:ENOV) are both medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

In the previous week, Enovis had 3 more articles in the media than MiniMed Group. MarketBeat recorded 5 mentions for Enovis and 2 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 0.96 beat Enovis' score of 0.21 indicating that MiniMed Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enovis	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiniMed Group currently has a consensus target price of $21.33, indicating a potential upside of 40.44%. Enovis has a consensus target price of $44.50, indicating a potential upside of 122.56%. Given Enovis' higher probable upside, analysts plainly believe Enovis is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Enovis	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

MiniMed Group has higher revenue and earnings than Enovis. MiniMed Group is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$2.99B	1.43	-$190.96M	-$0.68	N/A
Enovis	$2.25B	0.51	-$1.18B	-$19.88	N/A

19.7% of MiniMed Group shares are owned by institutional investors. Comparatively, 98.5% of Enovis shares are owned by institutional investors. 2.2% of MiniMed Group shares are owned by insiders. Comparatively, 2.9% of Enovis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

MiniMed Group has a net margin of 0.00% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
Enovis	-49.92%	10.32%	4.57%

Summary

MiniMed Group beats Enovis on 8 of the 15 factors compared between the two stocks.

How does Enovis compare to iRhythm Technologies?

Enovis (NYSE:ENOV) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Enovis had 2 more articles in the media than iRhythm Technologies. MarketBeat recorded 5 mentions for Enovis and 3 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.23 beat Enovis' score of 0.21 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
iRhythm Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enovis has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

98.5% of Enovis shares are owned by institutional investors. 2.9% of Enovis shares are owned by insiders. Comparatively, 1.0% of iRhythm Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Enovis currently has a consensus price target of $44.50, suggesting a potential upside of 122.56%. iRhythm Technologies has a consensus price target of $187.38, suggesting a potential upside of 50.47%. Given Enovis' higher possible upside, research analysts clearly believe Enovis is more favorable than iRhythm Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

iRhythm Technologies has a net margin of -3.53% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-49.92%	10.32%	4.57%
iRhythm Technologies	-3.53%	-10.26%	-1.39%

iRhythm Technologies has lower revenue, but higher earnings than Enovis. iRhythm Technologies is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.51	-$1.18B	-$19.88	N/A
iRhythm Technologies	$747.14M	5.48	-$44.55M	-$0.86	N/A

Summary

Enovis beats iRhythm Technologies on 9 of the 17 factors compared between the two stocks.

How does Enovis compare to Warby Parker?

Enovis (NYSE:ENOV) and Warby Parker (NYSE:WRBY) are both medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

In the previous week, Warby Parker had 3 more articles in the media than Enovis. MarketBeat recorded 8 mentions for Warby Parker and 5 mentions for Enovis. Warby Parker's average media sentiment score of 0.84 beat Enovis' score of 0.21 indicating that Warby Parker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Warby Parker	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Enovis presently has a consensus target price of $44.50, suggesting a potential upside of 122.56%. Warby Parker has a consensus target price of $29.82, suggesting a potential upside of 1.15%. Given Enovis' higher probable upside, analysts plainly believe Enovis is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67

Warby Parker has a net margin of 0.15% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Warby Parker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-49.92%	10.32%	4.57%
Warby Parker	0.15%	2.30%	1.18%

Enovis has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Warby Parker has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market.

Warby Parker has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.51	-$1.18B	-$19.88	N/A
Warby Parker	$871.91M	3.62	$1.64M	$0.02	1,473.90

98.5% of Enovis shares are held by institutional investors. Comparatively, 93.2% of Warby Parker shares are held by institutional investors. 2.9% of Enovis shares are held by company insiders. Comparatively, 16.8% of Warby Parker shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Warby Parker beats Enovis on 10 of the 15 factors compared between the two stocks.

Get Enovis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENOV vs. The Competition

Export

Metric	Enovis	MEDICAL INFO SYS Industry	Medical Sector	NYSE Exchange
Market Cap	$1.15B	$1.81B	$6.79B	$23.33B
Dividend Yield	N/A	N/A	2.66%	4.07%
P/E Ratio	-1.01	81.12	27.46	31.68
Price / Sales	0.51	7.85	582.89	21.92
Price / Cash	0.82	24.83	48.53	25.04
Price / Book	0.77	5.79	10.95	4.81
Net Income	-$1.18B	-$54.76M	$3.57B	$1.07B
7 Day Performance	-6.58%	7.08%	2.58%	1.59%
1 Month Performance	-7.99%	-0.02%	1.67%	2.81%
1 Year Performance	-39.39%	5.08%	35.92%	21.66%

Enovis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENOV Enovis	4.2514 of 5 stars	$20.00 -3.4%	$44.50 +122.6%	-33.9%	$1.15B	$2.25B	N/A	7,802	Analyst Downgrade
LIVN LivaNova	1.5105 of 5 stars	$78.71 +0.3%	$80.75 +2.6%	+82.7%	$4.31B	$1.39B	40.36	3,300
NVST Envista	1.0441 of 5 stars	$25.50 -1.6%	$28.67 +12.4%	+34.4%	$4.22B	$2.72B	62.20	12,000
MMED MiniMed Group	2.6646 of 5 stars	$14.22 -3.7%	$21.33 +50.0%	N/A	$3.99B	$2.99B	N/A	8,000
IRTC iRhythm Technologies	4.5465 of 5 stars	$104.69 +0.0%	$187.38 +79.0%	-22.7%	$3.44B	$787.85M	N/A	2,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ENOV) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enovis (ENOV) Competitors